Considering its higher binding affinity to VEGFR-2 compared with other anti-angiogenic drugs, apatinib might be able to offer further potential therapeutic opportunities for treating advanced cholangiocarcinoma, especially for patients with high expression of VEGF (34). The gene discussed is VEGFA; the disease is cholangiocarcinoma.